The first result of the present study is the demonstration that Gal-3 plasma levels increased linearly in the five risk strata based on the REVEAL 2.0 risk score, which is a validated, easily applied tool for predicting survival in patients with PAH. Here, LGALS3 is linked to pulmonary arterial hypertension.